|
|
|
|
| LEADER |
03581nam a2200925 i 4500 |
| 001 |
ZAG01000544558 |
| 003 |
HR-ZaZAG |
| 005 |
20121003092907.0 |
| 007 |
ta |
| 008 |
100422s2009 ci a rm 000 0dhrv d |
| 035 |
|
|
|a (HR-ZaZAG)000544558
|
| 040 |
|
|
|a HR-ZaMFK
|b hrv
|c HR-ZaMFK
|e ppiak
|
| 041 |
0 |
|
|a hrv
|b eng
|
| 060 |
|
4 |
|a WP 870
|
| 100 |
1 |
|
|a Bandić Pavlović, Daniela
|
| 245 |
1 |
0 |
|a Prognostička vrijednost tumorskih antigena MAGE-A4 i NY-ESO-1 u bolesnica s povratnim karcinomom dojke :
|b disertacija /
|c Daniela Bandić Pavlović.
|
| 260 |
|
|
|a Zagreb :
|b [s. n.],
|c 2009.
|
| 300 |
|
|
|a 127 str. :
|b ilustr. (djelomice u bojama), graf. prikazi ;
|c 30 cm. +
|e CD-ROM
|
| 500 |
|
|
|a Sažetak ; Summary: Prognostic significance of MAGE-A4 and NY-ESO-1 tumor antigens in recurrent breast cancer
|
| 502 |
|
|
|a Doktorska disertacija, Medicinski fakultet Sveučilišta u Zagrebu, 2009
|
| 504 |
|
|
|a Bibliografija: str. 110-126
|
| 530 |
|
|
|a Dostupno i na CD-ROM-u
|
| 650 |
1 |
9 |
|a Antigen, tumorski
|x analiza
|2 hrvmesh
|
| 650 |
1 |
9 |
|a Antigen, tumorski
|x imunologija
|2 hrvmesh
|
| 650 |
1 |
9 |
|a Dojka, tumori
|x imunologija
|2 hrvmesh
|
| 650 |
1 |
9 |
|a Dojka, tumori
|x mortalitet
|2 hrvmesh
|
| 650 |
1 |
9 |
|a Dojka, tumori
|x patologija
|2 hrvmesh
|
| 650 |
1 |
9 |
|a Karcinom, duktalni, dojka
|x patologija
|2 hrvmesh
|
| 650 |
1 |
9 |
|a Karcinom, duktalni, dojka
|x mortalitet
|2 hrvmesh
|
| 650 |
1 |
9 |
|a Karcinom, duktalni, dojka
|x sekundarne metastaze
|2 hrvmesh
|
| 650 |
1 |
9 |
|a Peptidni fragmenti
|x analiza
|2 hrvmesh
|
| 650 |
1 |
9 |
|a Peptidni fragmenti
|x imunologija
|2 hrvmesh
|
| 650 |
1 |
9 |
|a Tumorski proteini
|x analiza
|2 hrvmesh
|
| 650 |
1 |
9 |
|a Tumorski proteini
|x imunologija
|2 hrvmesh
|
| 650 |
2 |
9 |
|a DNK
|x analiza
|2 hrvmesh
|
| 650 |
2 |
9 |
|a Genska ekspresija, regulacija, tumorska
|2 hrvmesh
|
| 650 |
2 |
9 |
|a Imunohistokemija
|2 hrvmesh
|
| 650 |
2 |
9 |
|a Ljudi
|e check tag
|2 hrvmesh
|
| 650 |
2 |
9 |
|a Odrasla osoba
|2 hrvmesh
|
| 650 |
2 |
9 |
|a Osoba srednjih godina
|2 hrvmesh
|
| 650 |
2 |
9 |
|a Plodinost
|2 hrvmesh
|
| 650 |
2 |
9 |
|a Prognoza
|2 hrvmesh
|
| 650 |
2 |
9 |
|a Receptor, ERBB-2
|x analiza
|2 hrvmesh
|
| 650 |
2 |
9 |
|a Stanična proliferacija
|2 hrvmesh
|
| 650 |
2 |
9 |
|a Starija osoba
|2 hrvmesh
|
| 650 |
2 |
9 |
|a Stopa preživljavanja
|2 hrvmesh
|
| 650 |
2 |
9 |
|a Tumor, recidiv, lokalni
|2 hrvmesh
|
| 650 |
2 |
9 |
|a Ženska osoba
|e check tag
|2 hrvmesh
|
| 650 |
1 |
2 |
|a Antigens, Neoplasm
|x analysis
|
| 650 |
1 |
2 |
|a Antigens, Neoplasm
|x immunology
|
| 650 |
1 |
2 |
|a Breast Neoplasms
|x immunology
|
| 650 |
1 |
2 |
|a Breast Neoplasms
|x mortality
|
| 650 |
1 |
2 |
|a Breast Neoplasms
|x pathology
|
| 650 |
1 |
2 |
|a Carcinoma, Ductal, Breast
|x mortality
|
| 650 |
1 |
2 |
|a Carcinoma, Ductal, Breast
|x pathology
|
| 650 |
1 |
2 |
|a Carcinoma, Ductal, Breast
|x secondary
|
| 650 |
1 |
2 |
|a Neoplasm, Proteins
|x analysis
|
| 650 |
1 |
2 |
|a Neoplasm, Proteins
|x immunology
|
| 650 |
1 |
2 |
|a Peptide Fragments
|x analysis
|
| 650 |
1 |
2 |
|a Peptide Fragments
|x immunology
|
| 650 |
2 |
2 |
|a Adult
|
| 650 |
2 |
2 |
|a Aged
|
| 650 |
2 |
2 |
|a Cell Proliferation
|
| 650 |
2 |
2 |
|a DNA
|x analysis
|
| 650 |
2 |
2 |
|a ERBB-2
|x analysis
|
| 650 |
2 |
2 |
|a Female
|e check tag
|
| 650 |
2 |
2 |
|a Gene Expression Regulation, Neoplastic
|
| 650 |
2 |
2 |
|a Humans
|e check tag
|
| 650 |
2 |
2 |
|a Immunohistochemistry
|
| 650 |
2 |
2 |
|a Neoplasms, Recurrence, Local
|
| 650 |
2 |
2 |
|a Middle Aged
|
| 650 |
2 |
2 |
|a Ploides
|
| 650 |
2 |
2 |
|a Prognosis
|
| 650 |
2 |
2 |
|a Receptor
|
| 650 |
2 |
2 |
|a Survival Rate
|
| 945 |
0 |
|
|a Mentor: Antonio Juretić ;
|b 30. 04. 2009.
|
| 946 |
|
|
|a Ocjena rada: Jasminka Jakić-Razumović, Zdenko Stanec, Fedor Šantek ;
|b Obrana rada: Jasminka Jakić-Razumović, Zdenko Stanec, Fedor Šantek
|
| OWN |
|
|
|a MF
|